PMV PHARMACEUTICALS, INC. Proceeds from Issuance of Convertible Preferred Stock
PMV PHARMACEUTICALS, INC. (PMVP) reported Proceeds from Issuance of Convertible Preferred Stock of $69.79 million for the 12-month period ending 2020-12-31, per its 10-K filed 2023-03-01.
Discontinued › Cash Flow
us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock · last filed 2023-03-01
- PMV PHARMACEUTICALS, INC. proceeds from issuance of convertible preferred stock for the quarter ending 2020-12-31 was $0.00.
- PMV PHARMACEUTICALS, INC. proceeds from issuance of convertible preferred stock for fiscal 2020 was $69.79M, a 13.10% increase from fiscal 2019.
- PMV PHARMACEUTICALS, INC. proceeds from issuance of convertible preferred stock for fiscal 2019 was $61.70M.
| Period end | Proceeds from Issuance of Convertible Preferred Stock 3 month | Proceeds from Issuance of Convertible Preferred Stock 9 month | Proceeds from Issuance of Convertible Preferred Stock 12 month |
|---|---|---|---|
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | $69.79M 10-K · filed 2023-03-01 | |
| 2020-09-30 | $69.79M 10-Q · filed 2021-11-12 | ||
| 2019-12-31 | $61.70M 10-K · filed 2022-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Connect Biopharma Holdings Ltd (CNTB) | $0.069B | -2.17 | |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |